JP Morgan Chase
PTGX icon

JP Morgan Chase’s Protagonist Therapeutics PTGX Stock Holding History

JP Morgan Chase’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,000
Closed -$332K – 7661
2025
Q2 		$332K Buy
+6,000
New +$288K ﹤0.01% 4991
2024
Q4 		– Sell
-500
Closed -$22.5K – 7667
2024
Q3 		$22.5K Buy
+500
New +$20.2K ﹤0.01% 6214
2023
Q3 		– Sell
-218,900
Closed -$6.05M – 7673
2023
Q2 		$6.05M Buy
+218,900
New +$5.48M ﹤0.01% 2713

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

JP Morgan Chase's PTGX Position: Q1 2026 in Review

JP Morgan Chase increased its Protagonist Therapeutics (PTGX) stake by 11% in Q1 2026, buying an estimated $1.57M and bringing the position to 172,990 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

JP Morgan Chase first reported a position in PTGX in Q3 2016 and has held it in 38 quarters since. The position peaked at $24.6M in Q2 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • JP Morgan Chase held 172,990 shares of Protagonist Therapeutics worth $17.3M as of Q1 2026.
  • JP Morgan Chase bought 17,690 Protagonist Therapeutics shares in Q1 2026, an estimated $1.57M.
  • Protagonist Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2201 holding.
  • JP Morgan Chase first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • JP Morgan Chase's Protagonist Therapeutics position peaked at $24.6M in Q2 2025.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.